Cargando…
A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma
Multiple myeloma is an incurable cancer of bone marrow plasma cells, with a 5-year survival rate of 43%. Its incidence has increased by 126% since 1990. Treatment typically involves high-dose combination chemotherapy, but therapeutic response and patient survival are unpredictable and highly variabl...
Autores principales: | Rajeev Krishnan, Sabna, De Rubis, Gabriele, Suen, Hayley, Joshua, Douglas, Lam Kwan, Yiu, Bebawy, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070076/ https://www.ncbi.nlm.nih.gov/pubmed/32170169 http://dx.doi.org/10.1038/s41408-020-0304-7 |
Ejemplares similares
-
Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016) -
Circulating biosignatures in multiple myeloma and their role in multidrug resistance
por: Krishnan, S. Rajeev, et al.
Publicado: (2023) -
Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion
por: Jaiswal, Ritu, et al.
Publicado: (2017) -
Liquid biopsies for multiple myeloma in a time of precision medicine
por: Ferreira, Bruna, et al.
Publicado: (2020) -
Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)